Monoclonal Antibodies in the Treatment of at Risk Patients With COVID-19 to Reduce Hospitalization and Severe Disease

Released On
November 30, 2021

Expires On
November 30, 2022

Media Type

Completion Time
60 minutes

Infectious Disease, Pulmonology, Primary Care

COVID-19, Pulmonary Fibrosis, Respiratory

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by The France Foundation.

This activity is supported by an educational grant from GlaxoSmithKline.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of pulmonologists, infectious disease specialists, primary care providers, and other health care providers who may be involved in the management of patients with COVID-19.

Program Overview

Providers managing patients with COVID-19 are not knowledgeable about the latest evidence-based monoclonal antibody treatments available. Methods for delivering these treatments are also discussed.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the utility of administering monoclonal antibodies for the management of at-risk patients with COVID-19, including variants
  • Explain how management of COVID-19 with monoclonal antibodies affects viral load
  • Recognize specific IDSA and NIH guideline-recommended treatments for at-risk patients and select appropriate monoclonal antibody therapy for patients with COVID-19, including combination therapy
  • Describe the use of monoclonal antibodies in immunosuppressed patients with COVID-19
  • Discuss the safety and efficacy of the available and emerging monoclonal antibodies for the management of at-risk patients with COVID-19



Peter Chen, MD

Director, Pulmonary and Critical Care Medicine
Professor of Medicine and Biomedical Sciences
Medallion Chair in Molecular Medicine
Cedars-Sinai Medical Center
Los Angeles, CA


Lisa Lancaster, MD

Medical Director, Interstitial Lung Disease Program
Medical Advisor for Pulmonary Rehabilitation Program at Dayani Center
Vanderbilt University Medical Center
Nashville, TN

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Peter Chen, MD
  • Consultant: Eli Lilly
Lisa Lancaster, MD
  • Consultant: Genentech, AstraZeneca, BMS, Pliant, DevProPharmaceuticals, Galapagos, United Therapeutics, Veracyte, and Bellerophon
  • Speaker’s Bureau: Genentech, Boehringer Ingelheim, Veracyte, and United Therapeutics
  • Contracted Research: Celgene, Novartis, Galapagos, Galecto, Biogen, Boehringer Ingelheim, Respivant, Pliant, BMS, Fibrogen, Bellerophon, and Roche

Instructions for Participation and Credit

  1. There are no fees for participating in and receiving credit for this activity
  2. Review the activity objectives and CME/CE information
  3. Complete the CME/CE activity
  4. Complete the online posttest. A score of 80% is required to successfully complete this activity. The participant may take the test until successfully passed
  5. Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs
  6. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™, nursing credits, or a certificate of participation—your CME/CE certificate will be available for download

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The France Foundation equires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or